Delivery Order SPE2DB22D1106-SPE2DB25FFHJ6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,530.90 to AmerisourceBergen Drug Corp for Orilissa 150 mg tablets (7-count packages) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed price delivery order represents a non-competitive set-aside procurement and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was selected to supply this specialized...
- The Defense Logistics Agency awarded a delivery order valued at $6,308.10 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Orilissa 150 mg tablets (7-count packaging). This is a firm fixed-price, non-set-aside contract with a completion date of July 21, 2025, and performance in Conshohocken, Pennsylvania. Orilissa is an endometriosis treatment medication, representing the type of specialized pharmaceutical product that AmerisourceBergen routinely supplies to federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.91 to AmerisourceBergen Drug Corp for 7 tablets of Orilissa 150 mg on September 8, 2025, with a completion date of September 9, 2025. This firm fixed-price delivery order, which is not a set-aside contract, represents a procurement of the endometriosis medication Orilissa to support federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Orilissa 200 mg tablets (14-count packaging) with a ceiling value of $8,559.49 under a firm fixed-price contract. This non-set-aside award was competitively procured and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orilissa 150 mg tablets in quantities of 7 units, valued at $8,696.28. This firm fixed-price delivery order, which was not set-aside, was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a $6,382.34 firm fixed price delivery order to AmerisourceBergen Drug Corp for Orilissa 150 mg tablets (quantity of 7 units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside contract represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was made to AmerisourceBergen's corporate office, with performance occurring at the company's Conshohocken, Pennsylvania location. This...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Orilissa 150 mg tablets, a medication used to treat endometriosis. The award has a ceiling value of $3,100.78 and a completion date of June 26, 2025. This is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,290.82, is for the delivery of Orilissa 150 mg tablets. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of the medication Orilissa (Elagolix) 150 mg tablets. The contract has a ceiling value of $3,418.68 and a completion date of October 16, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Orilissa 150 mg tablets. The $11,137.57 contract has a completion date of May 7, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFHJ6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orilissa 150 mg tablets (quantity 7) under a firm fixed price contract valued at $2,280.66. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Orilissa (elagolix), a prescription medication for endometriosis treatment, represents one of numerous pharmaceutical products the contractor delivers through this framework contract to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/8/25 |